Aspirin resistance: Current status and role of tailored therapy

Clinical Cardiology

Volumn 35, Issue 11, 2012, Pages 673-680

  Grinstein, Jonathan ^a   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; FIBRINOGEN RECEPTOR; IBUPROFEN; PADGEM PROTEIN; PARACETAMOL; ROFECOXIB; THROMBOXANE A2;

ACUTE CORONARY SYNDROME; ANALYTIC METHOD; ANALYZER; ASPIRIN RESISTANCE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBESITY; PATIENT COMPLIANCE; POINT OF CARE TESTING; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; REVIEW; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; UNSPECIFIED SIDE EFFECT; WOMEN'S HEALTH;

EID: 84869488610     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22031     Document Type: Review

References (79)

1. Patrono C, Coller B, Fitzgerald GA, et al. Platelet active drugs: the relationships among dose, effectiveness, and side-effects. Chest. 2004;126:234S-264S.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
3. dummy Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2: 349-360.
4. Sanderson S, Emery J, Baglin T, et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005; 142: 370-380. (Pubitemid 40293410)
5. Sane DC, McKee SA, Malinin AI, et al. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol. 2002; 90: 893-895.
6. Frelinger AL, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1 and cyclooxygenase 2-independent pathway. A 700-patient study of aspirin resistance. Circulation. 2006; 113: 2888-2896. (Pubitemid 44297229)
7. FitzGerald R, Pirmohamed M., Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther. 2011; 130: 213-225.
8. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinder determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41: 961-965. (Pubitemid 36315537)
9. Reilly IAG, Fitzgerald GA., Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987; 69: 180-186. (Pubitemid 17007095)
10. Di Minno G, Silver MJ, Murphy S., Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood. 1983; 61: 1081-1085. (Pubitemid 13099894)
11. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007; 14: 1702-1708. (Pubitemid 47227104)
12. Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in health individuals and patients with coronary artery disease. Thromb Haemost. 2010; 103: 1245-1253.
13. Kamath S, Blann AD, Lip GY., Platelet activation: assessment and quantification. Eur Heart J. 2001; 22: 1561-1571. (Pubitemid 32801301)
14. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: a systematic review and metaanalysis. BMJ. 2008; 336: 195-198. (Pubitemid 351212675)
15. Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of platelet function by flow cytometry. Methods. 2000; 21: 259-270. (Pubitemid 32896750)
16. Blann AD, Lip GY., Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997; 128: 135-138. (Pubitemid 27092147)
17. Perneby C, Granstrom E, Beck O, et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. Thromb Res. 1999; 96: 427-436.
18. Faraday N, Becker DM, Yanek LR, et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol. 2006; 98: 774-779. (Pubitemid 44301012)
19. Hankey GJ, Eikelboom JW., Aspirin resistance. Lancet. 2006; 367: 606-616.
20. Michelson AD., Platelet function testing in cardiovascular diseases. Circulation. 2004; 110: e489-e493.
21. Van Werkum JW, Harmsze AM, Elsenberg HA, et al. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets. 2008; 19: 479-488.
22. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005; 118: 723-727. (Pubitemid 40897657)
23. Mammen EF, Comp PC, Gosselin R., PFA-100TM system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998; 24: 195-202. (Pubitemid 28180831)
24. Crescente M, Di Castelnuovo A, Iacoviello L, et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost. 2008; 99: 14-26.
25. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005; 95: 973-975. (Pubitemid 40487749)
26. Von Pape KW, Strupp G, Banzel T, et al. Effect of compliance and dosage adaption of long term aspirin on platelet function with PFA- 100ˆ in patients after myocardial infarction. Thromb Haemost. 2005; 94: 889-891. (Pubitemid 41489258)
27. Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007; 115: 2490-2496. (Pubitemid 46763222)
28. Goodman T, Ferro A, Sharma P., Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008; 66: 222-232.
29. Winocour PD., Platelet turnover in advanced diabetes. Eur J Clin Invest. 1994; 24 (Suppl 1): 34-37. (Pubitemid 24223519)
30. Arazi HC, Doiny DG, Torcivia RS, et al. Impaired antiplatelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact Cardiovasc Thorac Surg. 2010; 10: 863-867.
31. Hamsten A, Svensson J, Waldius G, et al. Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction. Am Heart J. 1985; 110: 1154-1160. (Pubitemid 16050238)
32. Grove EL, Hvas AM, Kristensen SD., Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009; 101: 151-156.
33. Henry P, Vermillet A, Boval B, et al. 24-hour time dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost. 2010; 105: 336-344.
34. Rocca B, Santilli F, Pitocco D, et al. Variability in the recovery rate of platelet cyclooxygenase activity during chronic therapy with low-dose aspirin in type 2 diabetes [Abstract]. Circulation. 2010; 122: A12233.
35. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345: 1809-1817.
36. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J Am Coll Cardiol. 2006; 47: 27-33. (Pubitemid 43005160)
37. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097-1105.
38. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol. 2009; 104: 525-530.
39. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002; 107: 45-49. (Pubitemid 35284424)
40. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
41. Buse JB, Ginsberg HN, Bakris GL, et al.; for the American Heart Association and American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007; 115: 114-126. (Pubitemid 46058619)
42. Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med. 2005; 83: 148-158. (Pubitemid 40379303)
43. Serebruany VL, Malinin AI, Pokov A, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the Plavix Use for Treatment of Diabetes (PLUTO-Diabetes) trial. Am Heart J. 2008; 155: 93.e1-93.e7.
44. Duzenli MA, Ozdemir K, Aygul N, et al. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. Am J Cardiol. 2008; 102: 396-400.
45. Santilli F, Davì G, Consoli A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol. 2006; 47: 391-397. (Pubitemid 43063260)
46. Tamminen M, Lassila R, Westerbacka J, et al. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord. 2003; 27: 907-911. (Pubitemid 36918612)
47. Bordeaux BC, Qayyum R, Yanek LR, et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol. 2010; 13: 56-62.
48. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes. 1999; 48: 426-429. (Pubitemid 29061122)
49. Konstantinides S, Schafer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001; 108: 1533-1540. (Pubitemid 33091991)
50. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293-1304.
51. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens. 2000; 18: 629-642. (Pubitemid 30303495)
52. Swain L, Hillman RS., Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the Women's Health Study. J Thromb Thrombolysis. 2009; 28: 94-100.
53. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006; 295: 1420-1427.
54. Qayyum R, Becker DM, Yanek LR, et al. Platelet Inhibition by aspirin 81 and 325mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol. 2008; 101: 1359-1363.
55. Aydinalp A, Atar I, Gulmez O, et al. The clinical significance of aspirin resistance in patients with chest pain. Clin Cardiol. 2010; 33: E1-E7.
56. Poulsen TS, JÃ̧rgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res. 2007; 119: 555-562. (Pubitemid 46321503)
57. Valles J, Santos MT, Fuset MP, et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2007; 99: 19-25. (Pubitemid 44969337)
58. Erne P, Wardle J, Sanders K, et al. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost. 1988; 59: 259-263.
59. Borna C, Lazarowski E, van Heusden C, et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J. 2005; 3: 10.
60. The CURRENT-OASIS Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363: 930-942.
61. Kaltoft A, Jensen LO, Maeng M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol. 2009; 53: 658-664.
62. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008; 52: 734-739.
63. Würtz M, Grove EL, Wulff LN, et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv. 2010; 3: 828-835.
64. Zimmermann N, Gams E, Hohlfeld T., Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg. 2008; 34: 93-108.
65. Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. Circulation. 1989; 80: 1190-1197. (Pubitemid 19282507)
66. Hyde JA, Chin JA, Graham TR., Platelets and cardiopulmonary bypass. Perfusion. 1998; 13: 389-409.
67. Ballotta A, Saleh HZ, El Baghdady HW, et al. Comparison of early platelet activation in patients undergoing on-pump versus off-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2007; 134: 132-138. (Pubitemid 46962015)
68. Wang Z, Gao F, Men J, et al. Aspirin resistance in off-pump coronary artery bypass grafting. Eur J Cardiothorac Surg. 2012; 41: 108-112.
69. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994; 308: 81-106.
70. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med. 1985; 313: 1369-1375.
71. Brown BG, Cukingnan RA, DeRouen T, et al. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation. 1985; 72: 138-146. (Pubitemid 15069586)
72. Barent R, Auer J, Franklin B, et al. Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. Am J Cardiol. 2011; 108: 644-650.
73. Hovens MMC, Snoep JD, Eikenboom JCJ, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007; 153: 175-181. (Pubitemid 46096871)
74. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the aspirin0induced platelet effect (ASPECT) study. Circulation. 2007; 115: 3156-3164. (Pubitemid 47012230)
75. Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011: 4: 180-187.
76. Neubauer H, Kaiser AF, Endres HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-the Bochum clopidogrel and aspirin plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011; 9: 3.
77. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015. (Pubitemid 350106708)
78. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
79. Gaglia MA, Waksman R., Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor. Circulation. 2011; 123: 451-456.